Edwards Lifesciences Corporation (EW) Issues Q4 Earnings Guidance
Edwards Lifesciences Corporation (NYSE:EW) updated its fourth quarter earnings guidance on Tuesday. The company provided EPS guidance of $0.84-0.94 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.91. The company issued revenue guidance of $855-895 million, compared to the consensus revenue estimate of $869.55 million.
Several equities analysts have weighed in on the company. Cowen and Company reissued a buy rating and set a $135.00 price objective on shares of Edwards Lifesciences Corporation in a report on Thursday, October 12th. Canaccord Genuity reissued a buy rating and set a $155.00 price objective on shares of Edwards Lifesciences Corporation in a report on Sunday, October 8th. Barclays PLC reissued an equal weight rating and set a $120.00 price objective on shares of Edwards Lifesciences Corporation in a report on Saturday, September 30th. Zacks Investment Research lowered Edwards Lifesciences Corporation from a strong-buy rating to a hold rating in a report on Tuesday, September 26th. Finally, Royal Bank Of Canada reissued a buy rating and set a $130.00 price objective on shares of Edwards Lifesciences Corporation in a report on Friday, September 1st. Seven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of Buy and an average price target of $120.75.
Shares of Edwards Lifesciences Corporation (EW) traded up 0.12% on Tuesday, hitting $114.25. The stock had a trading volume of 2,326,660 shares. The stock has a market cap of $24.12 billion, a PE ratio of 34.65 and a beta of 0.62. The company has a 50 day moving average price of $111.17 and a 200-day moving average price of $112.34. Edwards Lifesciences Corporation has a 12 month low of $81.12 and a 12 month high of $121.45.
Edwards Lifesciences Corporation (NYSE:EW) last announced its earnings results on Tuesday, October 24th. The medical research company reported $0.84 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.86 by ($0.02). The business had revenue of $821.50 million for the quarter, compared to analysts’ expectations of $833.85 million. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.68 earnings per share. On average, equities research analysts anticipate that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current year.
In related news, VP Larry L. Wood sold 18,960 shares of the company’s stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $108.54, for a total transaction of $2,057,918.40. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the company’s stock in a transaction dated Friday, July 28th. The shares were sold at an average price of $114.68, for a total transaction of $607,804.00. The disclosure for this sale can be found here. Insiders have sold a total of 201,161 shares of company stock worth $22,826,072 over the last quarter. 2.13% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY NOTICE: “Edwards Lifesciences Corporation (EW) Issues Q4 Earnings Guidance” was published by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/24/edwards-lifesciences-corporation-ew-issues-q4-earnings-guidance.html.
Edwards Lifesciences Corporation Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.